期刊文献+

埃索美拉唑治疗复合性溃疡临床疗效观察

下载PDF
导出
摘要 目的研究埃索美拉唑治疗消化性溃疡的疗效及安全性。方法将经胃镜证实的复合性溃疡患者随机分成埃索美拉唑组(治疗组,简称Eso组)和奥美拉唑组(对照组,简称Ome组),其中Eso组62例,应用埃索美拉唑20mg,2次/d,1周后改为按需服用;Ome组58例,应用奥美拉唑20 mg,2次/d。疗程6周。停药后均复查胃镜观察溃疡愈合情况。治疗期间每周随访1次,并记录症状改善情况及不良反应。结果Eso组的愈合率为87%,Ome组的愈合率为84.5%,P>0.05。疼痛消失时间及1周末症状消失率Eso组优于Ome组(P<0.05);4周末症状的改善情况两组无差异(P>0.05)。治疗期间,两组均有良好的耐受性。结论埃索美拉唑对复合性溃疡有较高的治愈率和症状改善率,总体疗效与奥美拉唑无差异,缓解症状方面优于奥美拉唑。
出处 《湘南学院学报(医学版)》 2007年第3期25-26,共2页 Journal of Xiangnan University(Medical Sciences)
  • 相关文献

参考文献4

  • 1[3]Kanazawa H,Okada A,Higake M,et al.Stereospecific analysis of omeprazole in human plasma as a probe for CYP2C19 phenotype[J].J Pharm Biomed Anal,2003,30(6):1817-1827
  • 2[4]Rohss K,Hasselgren G,Hedenstrom H.Effect of esomeprazloe 40mg vs omeprazole 40 mg on 24hour intragastric pH in patients with symptoms of gastroesophageal reflux disease[J].Dig Dis Sci,2002,47:954-958
  • 3[5]Lind T,Rydberg L,Kyleback A,et al.Esomeprazole provides mproved acid control vs omeprazole in patients with symptoms of Gastro-esophageal reflux disease[J].Aliment Pharmacol Ther,2000,14:861-867
  • 4湛先保,李兆申,程能能,杜奕奇,邹多武,尹宁,龚燕芳.埃索美拉唑对健康志愿者抑制胃泌酸的药效学研究[J].中华消化杂志,2004,24(12):711-714. 被引量:21

二级参考文献11

  • 1Wilder-Smith C, Rohss K, Claar-Nilsson C, et al. Esomeprazole 40 mg provides more effective acid control than rabeprazole 20 mg.Gut, 2000, 47(suppl 3) :A63.
  • 2Horai Y, Kimura M, Furuie H, et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP 2C19 genotypes. Aliment Pharmacol Ther, 2001, 15:793-803.
  • 3Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg)compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol, 2002, 97:575-583.
  • 4Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther, 2000, 14:1249-1258.
  • 5Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther, 2001, 15:1729-1736.
  • 6Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of ''on-demand'' therapy for 6 months. Aliment Pharmacol Ther, 2001, 15:347-354.
  • 7Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther, 2000,14: 861-867.
  • 8Tsuneoka T, Fukushima K, Matsuo Y, et al. Genotype analysis of the CYP 2C19 gene in the Japanese population. Life Sci, 1996,59:1711-1715.
  • 9Rohss K, Hasselgren G, Hedenstrom H. Effect of esomeprazloe 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci,2002,47: 954-958.
  • 10Rohss K, Claar-Nilsson C, Rydholm H,et al. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg. Gastroenterology, 2000, 118(suppl 2) :A20.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部